The trial will enroll approximately 400 pediatric, geriatric and oncology patients at three sites who will be treated with either the novel guide wire-assisted peripheral IV catheter or the current standard of care.
Telesso Technologies entered into a strategic agreement with Vascular Pathways in December 2008 to co-develop Vascular Pathways’s guide wire-assisted device with the funding of the clinical trial and to potentially acquire Vascular Pathways.
Nelson Stacks, CEO of Telesso, said: “This post-market study represents the advancement of an important innovation in medicine designed to reduce the safety risks and costs traditionally associated with peripheral IV catheter use. We are encouraged by the interest and positive feedback Telesso has received to date, and we look forward to announcing additional sites shortly with data review in the second-third quarter of 2009.”